Published Studies
Synopsis Pancreatic ductal adenocarcinoma (PDAC) shows progressive loss of SIRT3, a mitochondrial deacetylase whose downregulation correlates with poor patient survival. Using spontaneous and expe...
Read moreSynopsis Triple-negative breast cancer (TNBC) is a very aggressive cancer with few treatment options and a high ability to spread. This study found that TNBC cells use a process in their mitochond...
Read moreNicotinamide Riboside Enhances NK Cell Anti-Tumor Activity: Preclinical Findings
Synopsis Tumor-produced lactate weakens natural killer (NK) cells by causing lysine lactylation (Kla), disrupting NAD+ metabolism, and fragmenting mitochondria, which reduces cytotoxicity. Supplem...
Read moreNicotinamide Riboside and NMN Enhance CAR-T Cell Function in Aging: Preclinical Findings
Synopsis Chimeric antigen receptor (CAR) T cell therapy is a powerful cancer treatment, but its effectiveness declines with aging. This study found that CAR-T cells from aged female mice show mito...
Read moreSynopsis Bone cancer pain (BCP) disrupts mitochondrial function in spinal cord neurons, leading to damaged mitochondrial structure, reduced ATP production, and decreased membrane potential (MMP). ...
Read moreSynopsisProtecting mitochondria in CD8+ T cells is important for improving cancer immunotherapy. This study tested whether nicotinamide riboside (NR) could prevent T cell exhaustion. In lab models,...
Read moreObjectives To evaluate the feasibility and efficacy of a remote telehealth exercise program, with or without NR supplementation, on improving glucose homeostasis and muscle health in adult childho...
Read moreNicotinamide Riboside Enhances T Cell Function and Antitumor Immunity: Preclinical Findings
Synopsis Most current cancer immunotherapies mainly focus on activating type 1 immune responses, which help fight cancer, but long-term remission is rare. Our study shows that a type 2 immune prot...
Read moreAltering the NAD+/NADH Ratio in Reprograms the Metabolome in Glioblastoma: Preclinical Findings
Synopsis Glioblastoma multiforme (GBM) is the most aggressive and deadly form of brain cancer, known for its rapid growth and invasion into surrounding tissue. Because GBM cells rewire their metab...
Read moreFluorinated NR Enhances NAD+ Depletion in Glioblastoma Therapy: Preclinical Findings
Synopsis Glioblastoma is one of the most aggressive and treatment-resistant brain cancers, partly because its cells rely heavily on NAD+, a molecule vital for energy production and survival. The d...
Read moreNMRK2 Serves as a Diagnostic Biomarker for Renal Cell Carcinoma: Preclinical Findings
Synopsis Xp11.2 translocation renal cell carcinoma (tRCC) is a rare and aggressive form of kidney cancer that currently lacks reliable diagnostic tools and effective treatments. This study identif...
Read moreNAMPT Inhibition in Neuroendocrine Cancers and the Role of NAD+ Precursors: Preclinical Findings
Synopsis Nicotinamide phosphoribosyltransferase (NAMPT) is a key enzyme that helps cancer cells make NAD+, a molecule essential for energy production and survival. Drugs that block NAMPT (NAMPT in...
Read moreUsing Engineered Cancer Cells to Identify How Orphan Cytotoxins Work: Preclinical Findings
Synopsis Orphan cytotoxins are small molecules whose exact targets or mechanisms are unknown. Understanding how they work can reveal new research tools and potential therapies. To help identify th...
Read moreNicotinamide Riboside Hydrogel Enhances T Cell Therapy: Preclinical Findings
Synopsis T cell-based immunotherapy (TCBI) is a promising cancer treatment, but its success is often limited by weak immune activation, T cell exhaustion, and tumor immune evasion through the PD-1...
Read moreNicotinamide Riboside Slows Liver Cancer Growth and Metastasis: Preclinical Findings
SynopsisNicotinamide adenine dinucleotide (NAD+) metabolism has emerged as a target in cancer treatment. This study evaluated the effects of nicotinamide riboside (NR), a NAD+ precursor, on hepatoc...
Read moreBeyond Pellagra—NAD+ Deficiency in Aging and Disease: Review
SynopsisInterest in NAD+ has surged because low NAD+ levels are linked to many health problems, including metabolic diseases, neurodegeneration, reproductive disorders, cancer, and aging. Researche...
Read moreNicotinamide Riboside Restores NAD+ and Counters Tumor Hyperprogression: Preclinical Findings
Synopsis Immune checkpoint blockade (ICB) therapy can sometimes cause tumors to grow faster, a problem called hyperprogressive disease (HPD). This study found that when immune cells release interf...
Read moreTracking Nicotinamide Riboside Uptake in Cancer Cells: Preclinical Findings
Synopsis Researchers developed a bioluminescent probe (BiNR) to visualize how nicotinamide riboside (NR)—a vitamin B3–derived NAD+ booster—is taken up by cells and tissues in real time. This tool ...
Read moreMitochondrial Targeting Inhibits Breast Cancer Stem Cells: Preclinical Findings
SynopsisMitochondria are vital cell components that generate energy, build essential molecules, and support cell signaling. In cancer, mitochondria often adapt to fuel tumor growth by supplying the...
Read moreNicotinamide Riboside Mitigates Cancer Cachexia: Preclinical Findings
Synopsis Cancer cachexia, a severe condition seen in advanced cancer patients, causes muscle loss, weight loss, and fat breakdown, greatly reducing quality of life and survival. This study found t...
Read more